|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 1:7–30. 2016. View Article : Google Scholar
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 2:115–132. 2016. View Article : Google Scholar
|
|
3
|
Partin AW, Kattan MW, Subong EN, Walsh PC,
Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of
prostate-specific antigen, clinical stage, and Gleason score to
predict pathological stage of localized prostate cancer. A
multi-institutional update. JAMA. 277:1445–1451. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stamey TA, Caldwell M, McNeal JE, Nolley
R, Hemenez M and Downs J: The prostate specific antigen era in the
United States is over for prostate cancer: What happened in the
last 20 years? J Urol. 172:1297–1301. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zare-Mirzaie A, Balvayeh P, Imamhadi MA
and Lotfi M: The frequency of latent prostate carcinoma in
autopsies of over 50 years old males, the Iranian experience. Med J
Islam Repub Iran. 2:73–77. 2012.
|
|
6
|
Du P, Kumar M, Yao Y, Xie Q, Wang J, Zhang
B, Gan S, Wang Y and Wu AM: Genome-wide analysis of the TPX2 family
proteins in Eucalyptus grandis. BMC Genomics. 1:9672016. View Article : Google Scholar
|
|
7
|
Tulu US, Fagerstrom C, Ferenz NP and
Wadsworth P: Molecular requirements for kinetochore-associated
microtubule formation in mammalian cells. Curr Biol. 16:536–541.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shao C, Duan C, Wang J, Luan S, Gao Y, Jin
D, Wang D, Li Y and Xu L: Expression of microtubule-associated
protein TPX2 in human gastric carcinoma and its prognostic
significance. Cancer Cell Int. 16:792016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tomii C, Inokuchi M, Takagi Y, Ishikawa T,
Otsuki S, Uetake H, Kojima K and Kawano T: TPX2 expression is
associated with poor survival in gastric cancer. World J Surg
Oncol. 1:142017. View Article : Google Scholar
|
|
10
|
Yang Y, Li DP, Shen N, Yu XC, Li JB, Song
Q and Zhang JH: TPX2 promotes migration and invasion of human
breast cancer cells. Asian Pac J Trop Med. 12:1064–1070. 2015.
View Article : Google Scholar
|
|
11
|
Miwa T, Kokuryo T, Yokoyama Y, Yamaguchi J
and Nagino M: Therapeutic potential of targeting protein for Xklp2
silencing for pancreatic cancer. Cancer Med. 4:1091–1100. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang Y, Guo W and Kan H: TPX2 is a
prognostic marker and contributes to growth and metastasis of human
hepatocellular carcinoma. Int J Mol Sci. 15:18148–18161. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei P, Zhang N, Xu Y, Li X, Shi D, Wang Y,
Li D and Cai S: TPX2 is a novel prognostic marker for the growth
and metastasis of colon cancer. J Transl Med. 11:3132013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Q, Yang P, Tu K, Zhang H, Zheng X and
Yao Y: TPX2 knockdown suppressed hepatocellular carcinoma cell
invasion via inactivating AKT signaling and inhibiting MMP2 and
MMP9 expression. Chin J Cancer Res. 26:410–417. 2014.PubMed/NCBI
|
|
15
|
Takahashi Y, Sheridan P, Niida A, Sawada
G, Uchi R, Mizuno H, Kurashige J, Sugimachi K, Sasaki S, Shimada Y,
et al: The AURKA/TPX2 axis drives colon tumorigenesis cooperatively
with MYC. Ann Oncol. 26:935–942. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aushev VN, Lee E, Zhu J, Gopalakrishnan K,
Li Q, Teitelbaum SL, Wetmur J, Esposti Degli D, Hernandez-Vargas H,
Herceg Z, et al: Novel predictors of breast cancer survival derived
from miRNA activity analysis. Clin Cancer Res. 24:581–591. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fu X, Chen G, Cai ZD, Wang C, Liu ZZ, Lin
ZY, Wu YD, Liang YX, Han ZD, Liu JC and Zhong WD: Overexpression of
BUB1B contributes to progression of prostate cancer and predicts
poor outcome in patients with prostate cancer. Onco Targets Ther.
9:2211–2220. 2016.PubMed/NCBI
|
|
18
|
Zeng J, Liu W, Fan YZ, He DL and Li L:
PrLZ increases prostate cancer docetaxel resistance by inhibiting
LKB1/AMPK-mediated autophagy. Theranostics. 8:109–123. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dávila-González D, Choi DS, Rosato RR,
Granados-Principal SM, Kuhn JG, Li WF, Qian W, Chen W, Kozielski
AJ, Wong H, et al: Pharmacological inhibition of NOS activates
ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in
triple-negative breast cancer. Clin Cancer Res. 24:1152–1162. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Garrido G and Vernos I: Non-centrosomal
TPX2-dependent regulation of the aurora A kinase: Functional
implications for healthy and pathological cell division. Front
Oncol. 6:882016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fu J, Bian M, Xin G, Deng Z, Luo J, Guo X,
Chen H, Wang Y, Jiang Q and Zhang C: TPX2 phosphorylation maintains
metaphase spindle length by regulating microtubule flux. J Cell
Biol. 10:373–383. 2015. View Article : Google Scholar
|
|
22
|
de Castro Perez I and Malumbres M: Mitotic
stress and chromosomal instability in cancer: The case for TPX2.
Genes Cancer. 3:721–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gu JJ, Zhang JH, Chen HJ and Wang SS: TPX2
promotes glioma cell proliferation and invasion via activation of
the AKT signaling pathway. Oncol Lett. 12:5015–5022. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen QI, Cao B, Nan N, Wang YU, Zhai XU,
Li Y and Chong T: TPX2 in human clear cell renal carcinoma:
Expression, function and prognostic significance. Oncol Lett.
5:3515–3521. 2016. View Article : Google Scholar
|
|
25
|
Vainio P, Mpindi JP, Kohonen P, Fey V,
Mirtti T, Alanen KA, Perala M, Kallioniemi O and Lljin K:
High-throughput transcriptomic and RNAi analysis identifies AIM1,
ERGIC1, TMED3 and TPX2 as potential drug targets in prostate
cancer. PLoS One. 7:e398012012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lohiya V, Aragon-Ching JB and Sonpavde G:
Role of chemotherapy and mechanisms of resistance to chemotherapy
in metastatic castration-resistant prostate cancer. Clin Med
Insights Oncol. 10 Suppl 1:S57–S66. 2016.
|
|
27
|
Antonarakis ES and Armstrong AJ: Evolving
standards in the treatment of docetaxel-refractory
castration-resistant prostate cancer. Prostate Cancer Prostatic
Dis. 14:192–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamashita S, Kohjimoto Y, Iguchi T, Koike
H, Kusumoto H, Iba A, Kikkawa K, Kodama Y, Matsumura N and Hara I:
Prognostic factors and risk stratification in patients with
castration-resistant prostate cancer receiving docetaxel-based
chemotherapy. BMC Urol. 16:132016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang RC, Chen X, Parissenti AM, Joy AA,
Tuszynski J, Brindley DN and Wang Z: Sensitivity of
docetaxel-resistant MCF-7 breast cancer cells to
microtubule-destabilizing agents including vinca alkaloids and
colchicine-site binding agents. PLoS One. 12:e01824002017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pan HW, Su HH, Hsu CW, Huang GJ and Wu TT:
Targeted TPX2 increases chromosome missegregation and suppresses
tumor cell growth in human prostate cancer. Onco Targets Ther.
10:3531–3543. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Banerjee S, Singh SK, Chowdhury I, Lillard
JW Jr and Singh R: Combinatorial effect of curcumin with docetaxel
modulates apoptotic and cell survival molecules in prostate cancer.
Front Biosci (Elite Ed). 9:235–245. 2017.PubMed/NCBI
|
